domvanalimab,etrumadenant,zimberelimab
arcus biosciences
['arc-7']
arc-7 update from #asco2023 virtual plenary series sees interesting results of use of anti-tigit (dom) in combination with anti pdl1 (zim) 
Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18